These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 28901856)

  • 41. The emerging role of interleukin (IL)-1 in the pathogenesis and treatment of inflammatory and degenerative eye diseases.
    Fabiani C; Sota J; Tosi GM; Franceschini R; Frediani B; Galeazzi M; Rigante D; Cantarini L
    Clin Rheumatol; 2017 Oct; 36(10):2307-2318. PubMed ID: 28032234
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ophthalmic Drug Delivery Using Iontophoresis: Recent Clinical Applications.
    Perez VL; Wirostko B; Korenfeld M; From S; Raizman M
    J Ocul Pharmacol Ther; 2020 Mar; 36(2):75-87. PubMed ID: 31755807
    [No Abstract]   [Full Text] [Related]  

  • 43. Clinical correlations of dry eye syndrome and allergic conjunctivitis in Korean children.
    Kim TH; Moon NJ
    J Pediatr Ophthalmol Strabismus; 2013; 50(2):124-7. PubMed ID: 23316947
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular and cellular biomarkers in dry eye disease and ocular allergy.
    Enríquez-de-Salamanca A; Bonini S; Calonge M
    Curr Opin Allergy Clin Immunol; 2012 Oct; 12(5):523-33. PubMed ID: 22895048
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Emerging therapeutics for ocular surface disease.
    Bielory BP; Shah SP; O'Brien TP; Perez VL; Bielory L
    Curr Opin Allergy Clin Immunol; 2016 Oct; 16(5):477-86. PubMed ID: 27585059
    [TBL] [Abstract][Full Text] [Related]  

  • 46. ICON: Diagnosis and management of allergic conjunctivitis.
    Bielory L; Delgado L; Katelaris CH; Leonardi A; Rosario N; Vichyanoud P
    Ann Allergy Asthma Immunol; 2020 Feb; 124(2):118-134. PubMed ID: 31759180
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of the ocular surface microbiome in allergic eye diseases.
    Cavuoto KM; Galor A; Zhu AY
    Curr Opin Allergy Clin Immunol; 2023 Oct; 23(5):376-382. PubMed ID: 37459276
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment.
    Ono SJ; Abelson MB
    J Allergy Clin Immunol; 2005 Jan; 115(1):118-22. PubMed ID: 15637556
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immune Relevant Models for Ocular Inflammatory Diseases.
    Gilger BC
    ILAR J; 2018 Dec; 59(3):352-362. PubMed ID: 29474707
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The antiallergic eye drops "polynadyme": development, experimental and clinical studies].
    Maĭchuk IuF; Pozdniakov VI; Pozdniakova VV; Iakushina LN
    Vestn Oftalmol; 2006; 122(5):35-8. PubMed ID: 17087034
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Classification of ocular allergy.
    Hodges MG; Keane-Myers AM
    Curr Opin Allergy Clin Immunol; 2007 Oct; 7(5):424-8. PubMed ID: 17873583
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recent advances in uveitis therapy: focus on selected phase 2 and 3 clinical trials.
    Thng ZX; Bromeo AJ; Mohammadi SS; Khatri A; Tran ANT; Akhavanrezayat A; T T Than N; Nguyen KS; Yoo WS; Mobasserian A; Or CCM; Nguyen QD
    Expert Opin Emerg Drugs; 2023 Dec; 28(4):297-309. PubMed ID: 38129984
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Allergic conjunctivitis and H1 antihistamines.
    del Cuvillo A; Sastre J; Montoro J; Jáuregui I; Dávila I; Ferrer M; Bartra J; Mullol J; Valero A
    J Investig Allergol Clin Immunol; 2009; 19 Suppl 1():11-8. PubMed ID: 19476049
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dry Eye Treatment Based on Contact Lens Drug Delivery: A Review.
    Guzman-Aranguez A; Fonseca B; Carracedo G; Martin-Gil A; Martinez-Aguila A; Pintor J
    Eye Contact Lens; 2016 Sep; 42(5):280-8. PubMed ID: 26372476
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation.
    Ratay ML; Bellotti E; Gottardi R; Little SR
    Adv Healthc Mater; 2017 Dec; 6(23):. PubMed ID: 29034584
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [0.05% cyclosporine a for treatment of chronic severe ocular surface disease].
    Nochez Y; Denoyer A; Pisella PJ
    Can J Ophthalmol; 2009 Aug; 44(4):406-11. PubMed ID: 19606161
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Punctal plug: a medical device to treat dry eye syndrome and for sustained drug delivery to the eye.
    Yellepeddi VK; Sheshala R; McMillan H; Gujral C; Jones D; Raghu Raj Singh T
    Drug Discov Today; 2015 Jul; 20(7):884-9. PubMed ID: 25668579
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [New aspects in drug therapy of ocular allergies].
    Maĭchuk IuF
    Vestn Oftalmol; 2000; 116(5):10-4. PubMed ID: 11221368
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ocular immunosuppressive microenvironment and novel drug delivery for control of uveitis.
    Teabagy S; Wood E; Bilsbury E; Doherty S; Janardhana P; Lee DJ
    Adv Drug Deliv Rev; 2023 Jul; 198():114869. PubMed ID: 37172782
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The practical detection of mmp-9 diagnoses ocular surface disease and may help prevent its complications.
    Kaufman HE
    Cornea; 2013 Feb; 32(2):211-6. PubMed ID: 22673852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.